肌动蛋白相关蛋白2调控人抗原R稳定性对非小细胞肺癌细胞放疗抵抗的影响

目的 探讨肌动蛋白相关蛋白2(ARPC2)通过人抗原R(HuR)对肺癌细胞放疗抵抗的影响.方法 将肺癌细胞根据不同处理,分为7组,ARPC2过表达组(使用ARPC2过表达慢病毒感染肺癌细胞)、ARPC2敲低组(使用shARPC2敲低慢病毒感染肺癌细胞)、HuR过表达组(使用HuR过表达慢病毒感染肺癌细胞)、HuR敲低组(使用shHuR敲低慢病毒感染肺癌细胞)、ARPC2过表达的同时HuR敲低组(同时使用ARPC2过表达和shHuR敲低慢病毒感染肺癌细胞)、ARPC2敲低的同时HuR过表达组(同时使用shHuR敲低和HuR过表达慢病毒感染肺癌细胞)、对照组(使用空载体慢病毒感染肺癌细胞).6 Gy的电离辐射处理后,流式细胞术检测各组肺癌细胞(A549、Calu-1、HCC827、MSTO-211H、NCI-H1299、NCI-H520、SK-MES-1)的凋亡水平.免疫印迹法检测肺癌细胞中HuR的蛋白表达水平.通过凋亡水平指示肺癌细胞的放疗抵抗.通过HuR的表达水平的半衰期以指示HuR的稳定性.比较用非配对双尾t检验,多组间比较则采用方差分析.结果 A549(0.43±0.08、1.88±0.15)、Calu-1(0.38±0.05、1.90±0.14)、HCC827(0.37±0.07、1.89±0.23)、MSTO-211H(0.39±0.06、1.95±0.29)、NCI-H1299(0.40±0.07、1.92±0.32)、NCI-H520(0.42±0.10、1.85±0.30)、SK-MES-1(0.44±0.09、1.90±0.33)中 ARPC2 的 mRNA 和蛋白表达水平高于人正常肺细胞 BEAS-2(0.12±0.03、1.19±0.19)、BNHLF(0.08±0.02、1.16±0.20,t=11.473、14.100、13.825、15.627、18.364、20.594、24.504、9.107、10.335、9.634、11.910、10.882、9.027、10.658,P<0.05).电离辐射处理组中 ARPC2 的蛋白表达水平(0.81±0.15、1.25±0.25、0.63±0.12,0.51±0.10、0.64±0.15、1.86±0.30、0.85±0.14)高于未处理组(0.17±0.04、0.15±0.04、0.16±0.04,0.17±0.05、0.16±0.04、0.17±0.05、0.18±0.06,t=13.037、21.035、13.610、7.331、9.925、28.567、14.814,P<0.05).电离辐射处理后ARPC2过表达组肺癌细胞的凋亡[(16.48±6.11)%、(16.03±5.35)%、(18.28±8.22)%、(24.70±9.71)%、(17.68±9.11%)]低于对照组[(47.92±6.58)%、(55.31±6.94)%、(51.29±7.16)%、(51.96±9.17)%、(54.16±2.24)%,t=11.071、14.183、9.579、6.453、12.311,P<0.05],ARPC2 敲低组肺癌细胞的凋亡[(70.47±8.46)%、(84.16±0.73)%、(76.71±1.87)%、(76.05±0.47)%、(88.07±9.14)%]高于对照组[(55.21±6.29)%、(51.59±7.04)%、(50.07±5.33)%、(47.14±7.53)%、(44.41±9.38)%,t=4.584、14.550、14.912、12.124、10.543,P<0.05].ARPC2 过表达组中 HuR、p-HuR、JAK1、p-STAT3 的蛋白表达水平(0.81±0.11、0.92±0.14、0.55±0.10、0.63±0.12)高于对照组(0.15±0.03、0.14±0.04、0.15±0.03、0.16±0.05,t=18.305、22.614、8.391、11.287,P<0.05),ARPC2 敲低组中 HuR、p-HuR、JAK1、p-STAT3 的蛋白表达水平(0.19±0.05、0.15±0.04、0.14±0.03、0.17±0.05)低于对照组(0.90±0.15、0.85±0.13、0.63±0.12、0.71±0.14,t=14.200、15.628、11.307、13.462,P<0.05).ARPC2 过表达组[(11.32±0.26)、(10.17±0.22)、(10.49±0.21)、(10.17±0.03)、(10.53±0.06)h]相较对照组 HuR 半衰期[(5.61±1.31)、(5.30±2.53)、(5.72±1.95)、(5.34±0.70)、(5.86±1.09)h]延长(t=13.523、6.056、7.691、21.819、13.533,P<0.05),ARPC2 敲低组[(2.02±0.71)、(2.96±1.23)、(2.61±0.68)、(3.04±0.82)、(2.23±0.22)h]相较于对照组 HuR 半衰期[(4.92±1.69)、(5.05±0.45)、(5.38±0.56)、(5.64±0.21)、(4.62±0.37)h]缩短(t=5.012、5.047、9.941、9.714、17.558,P<0.05).电离辐射处理后,HuR 过表达组(23.01±3.83、17.30±6.59、21.10±4.58、16.44±9.04、23.36±4.56)比对照组(47.30±6.59、51.10±4.58、46.44±9.00、53.36±9.56、45.97±2.54)可抑制肺癌细胞的凋亡(t=10.077、13.322、7.935、8.869、13.716,P<0.05),HuR 敲低组(80.90±17.46、72.24±10.84、77.82±18.9、84.16±10.98、83.50±11.54)比对照组能促进肺癌细胞的凋亡(t=5.693、4.918、5.163、6.025、5.925,P<0.05).结论 ARPC2通过提高HuR的蛋白稳定性促进了肺癌细胞的放疗抵抗.

放疗增效方中药配合三维适形放疗治疗食管癌疗效观察

目的观察放疗增效方配合三维适形放疗对非小细胞肺癌患者疗效的影响。方法观察组42例,采用放疗增效方中药配合三维适形放疗,持续至放疗结束;对照组35例,行单纯三维适形放疗,未服用中药。两组治疗前后分别进行近期疗效、不良反应、卡氏评分评估。结果治疗后,观察组KPS评分显著高于对照组;对防治放疗引起的副反应如白细胞下降、消化道反应及皮肤反应方面,观察组优于对照组。结论放疗增效方中药可提高食管癌患者三维适形放疗的生活质量,减轻毒副作用,可作为食管癌放疗的辅助用药。

非小细胞肺癌软脑膜转移通过Ommaya囊注射与腰椎穿刺术给药方式疗效的比较

目的观察通过腰椎穿刺术直接给药以及植入Ommaya囊给药两种鞘内注射培美曲塞途径,对非小细胞肺癌软脑膜转移患者的疗效的影响。方法回顾性分析2021年10月~2023年7月在广西医科大学附属肿瘤医院确诊为非小细胞肺癌伴软脑膜转移32例患者的临床资料。治疗组将接受放疗+培美曲塞鞘内注射+阿美替尼口服治疗脑膜癌病22例,其中ommaya囊组采取ommaya囊室内给药10例,腰穿组采取腰穿注射给药12例。对照组予以放疗+阿美替尼口服治疗10例。治疗Ommaya囊组患者行Ommaya术,术后给予放疗+靶药(阿美替尼)+脑室内化疗(注射培美曲塞);腰穿组患者行放疗+靶药(阿美替尼)+鞘内化疗(注射培美曲塞)。放疗方案:全脑照射每次3 Gy,每周5次,1疗程2周。口服靶药方案:阿美替尼110 mg,每天一次口服使用。化疗培美曲塞30 mg,d1、d8,3周方案,持续化疗至无法耐受或者死亡。结果ommaya囊组与腰穿组在生存时间,治疗前后MRS、Bathel指数评分均优于对照组(P<0.05),治疗组2组间无显著统计学差异(P>0.05)。结论本研究发现鞘内给药包括通过腰椎穿刺术直接给药以及植入Ommaya囊给药两种鞘内注射培美曲塞途径治疗小细胞肺癌软脑膜转移患者优于口服给药,提示这两种给药途径具有较好的应用前景。然而,由于样本量较小等不足,本研究的结论还需要将来更大样本的前瞻性研究来证实。

放疗增效方中药配合三维适形放疗治疗Ⅲ期食管癌术后患者疗效观察

目的观察放疗增效方配合三维适形放疗对食管癌术后Ⅲ期患者疗效的影响。方法研究组42例，采用放疗增效方中药配合三维适形放疗，持续至放疗结束；对照组35例，行单纯三维适形放疗，未服用中药。两组治疗前后分别进行生存率、不良反应、卡氏评分评估。结果治疗后，研究组生存率高于对照组，研究组1、2和3年生存率分别为59．5％，45．2％和30．9％，而对照组分别为57．1％，40．0％和14．3％，但差异无显著性（P〉0．05）；研究组KPS评分显著高于对照组；对防治放疗引起的副反应如白细胞下降、消化道反应及皮肤反应方面，观察组优于对照组。结论放疗增效方中药可提高食管癌术后Ⅲ期患者三维适形放疗的生活质量，减轻毒副作用，可作为食管癌放疗的辅助用药。

Treatment of Unresectable Advanced Gastric Cancer Using lodine-125 Brachytherapy

OBJECTIVE The purpose of the study was to examine the efficacy of treating patients with advanced gastric cancer using iodine-125 （^125Ⅰ） brachytherapy. METHODS Ten patients with unresectable advanced gastric cancer were selected based on their pattern of CT scans. We utilized a brachytherapy planning system to determine the distribution of the ^125Ⅰ seeds, their activity and quantity. The matched peripheral dose （MPD） was 110-135 Gy.^125Ⅰ seeds were implanted in a single plane or biplane by an intraoperative small incision or percutaneous puncture. The postoperative hemogram, CT, KPS, pain-relieving period and survival period were recorded. RESULTS One patient developed a complete response （CR）, 4 patients a partial response （PR）, 3 patients showed no change （NC） and 2 patients developed progressive disease （PD）. The overall response rate （CR＋PR） was 50% （5/10）. The pain-relieving rate was 89% （8/9）. The patients＇ appetite and KPS were improved. The longest survival period was 10 months and median life span was 4 months. There were 8 patients whose seeds fell off resulting in an expulsion rate of 3.8% （26/692）. The patients showed 0-1 degree acute radio-therapeutic side-effects without other symptoms such as abdominal pain, vomitus cruentes or intestinal obstruction etc.CONCLUSION Applying ^125Ⅰ implantation to treat advanced gastric cancer with a reasonable seed distribution can significantly improve clinical symptoms and their quality of life. The radioactive damage is mild. This method can be used as an important supplementary treatment for unresectable advanced gastric cancer.

Gefitinib combined with γ-ray stereotactic body radiation therapy has better efficacy than gefitinib alone for senile lung adenocarcinoma patients with EGFR mutations as first-line regimen

Objective： The senile lung adenocarcinoma patients harboring an activating epidermal growth factor receptor （EGFR） mutation shows good and rapid response to EGFR tyrosine kinase inhibitors （TKIs）. Whether gefitinib combined with y-ray stereotactic body radiation therapy has better efficacy than gefitinib alone for senile lung adenocarcinoma patients with EGFR mutations as first-line regimen is still under investigation. Methods： The 42 senile lung adenocarcinoma patients with EGFR mutations were divided into 2 groups according to the therapy method. Group A was the 22 patients treated with gefitinib combined with y-ray stereotactic body radiation therapy （SBRT）. Group B was the 20 patients treated with gefitinib alone. All of the patients received gefitinib of 250 mg/d from the first day until disease progression or other reasons. The patients of Group A were treated with y-ray stereotactic body radiation therapy from the second day. Radiation fields included the primary lesions and the integration of lymph nodes. Dose curve of this group was 50%-80%. Encircled dose was 4.0-6.5 Gy per fraction and the range of total dose was 40-52 Gy. We treated the patients 8-12 times and treated five times every week. Results： All the patients were examined by enhanced double helix CT at the second month. The tumor response rate （RR） of group A was 81.8% （18/22）. Disease control rate （DCR） was 90.9% （20/22）. The median overall survival （OS） was 24.2 months （range 8-58 months ） and the progression-free survival （PFS） was 18.6 months. The overall 1-year survival rate was 72.3% （16/22） and 2-year survival rate was 54.5% （12/22）. The main side effects included skin rash and diarrhea. The RR of group B was 50.0 % （10/20）. DCR was 75.0% （15/20）. OS was 17.4 months （range 6-32 months ） and PFS was 12.1 months. The overall 1-year survival rate was 60.0% （12/20） and 2-year survival rate was 40.0% （8/20）. The main side effects included skin rash and diarrhea. The group A who were treated with gefitinib combined with y-ray stereotactic body radiation therapy had a higher short term therapeutic effects （RR） and long term therapeutic effects （OS） than group B who were treated with gefitinib alone respectively （81.8% vs 50.0%, P = 0.029 〈 0.05, x2 = 4.773 and 24.2 vs 17.4, P = 0.024 〈 0.05, X2 = 5.098）. Conclu. sion： Gefitinib combined with y-ray stereotactic body radiation therapy has better efficacy than gefitinib alone for senile lung adenocarcinoma patients with EGFR mutations as first-line regimen. The side affects are acceptable.

New methods for the management of esophageal varices

Bleeding from esophageal varices (EVs) is a catastrophic complication of chronic liver disease. Many years ago, surgical procedures such as esophageal transection or distal splenorenal shunting were the only treatments for EVs. In the 1970s, interventional radiology procedures such as transportal obliteration, left gastric artery embolization, and partial splenic artery embolization were introduced, improving the survival of patients with bleeding EVs. In the 1980s, endoscopic treatment, endoscopic injection sclerotherapy (EIS), and endoscopic variceal ligation (EVL), further contributed to improved survival. We combined IVR with endoscopic treatment or EIS with EVL. Most patients with EVs treated endoscopically required follow- up treatment for recurrent varices. Proper management of recurrent EVs can significantly improve patients’ quality of life. Recently, we have performed EVL at 2-mo (bimonthly) intervals for the management of EVs. Longer intervals between treatment sessions resulted in a higher rate of total eradication and lower rates of recurrence and additional treatment.

Radiotherapy for multiple brain metastases from hepatocellular carcinomas

A 78-year-old man with liver cirrhosis was found to have multiple hepatocellular carcinomas （HCCs） and underwent 3 sessions of transcatheter arterial chernoernbolization. Fourteen months after diagnosis, the patient presented with left herniparesis. Contrast- enhanced magnetic resonance imaging showed multiple metastases with ring-shaped enhancement in the cerebrum and cerebellum. There were no metastases to other organs. The metastatic lesions almost completely disappeared after whole-brain radiotherapy with a total dose of 50 Gy. Neurologic symptoms decreased, and the patient＇s quality of life improved. The patient underwent 2 more sessions of transcatheter arterial chemoembolization. Twelve months after the diagnosis of brain metastasis, the patient remains alive. The present case indicates that radiotherapy can improve quality of life and prolong survival in some patients with brain metastases from HCCs.

Magnifying endoscopy in upper gastroenterology for assessing lesions before completing endoscopic removal

Any prognosis of gastrointestinal (GI) cancer is closely related to the stage of the disease at diagnosis.Endoscopic submucosal dissection (ESD) and en bloc endoscopic mucosal resection (EMR) have been performed as curative treatments for many early-stage GI lesions in recent years.The technologies have been widely accepted in many Asian countries because they are minimally invasive and supply thorough histopathologic evaluation of the specimens.However,before engaging in endoscopic therapy,an accurate diagnosis is a precondition to effecting the complete cure of the underlying malignancy or carcinoma in situ.For the past few years,many new types of endoscopic techniques,including magnifying endoscopy with narrow-band imaging (MENBI),have emerged in many countries because these methods provide a strong indication of early lesions and are very useful in determining treatment options before ESD or EMR.However,to date,there is no comparable classification equivalent to "Kudo's Pit Pattern Classification in the colon",for the upper GI,there is still no clear internationally accepted classification system of magnifying endoscopy.Therefore,in order to help unify some viewpoints,here we will review the defining optical imaging characteristics and the current representative classifications of microvascular and microsurface patterns in the upper GI tract under ME-NBI,describe the accurate relationship between them and the pathological diagnosis,and their clinical applications prior to ESD or en bloc EMR.We will also discuss assessing the differentiation and depth of invasion,defying the lateral spread of involvement and targeting biopsy in real time.

The Relationship between Serum VEGF Expression and PET/CT Images in TNM-staging of Lung Carcinoma

OBJECTIVE To analyze the relationship between the characteristics of PET/CT images for lung carcinoma(LC)TNM staging and the expression of serum VEGF protein. METHODS PET/CT examinations were performed before treatment of 53 patients with LC.The expression of serum VEGF protein was examined using a quantitative sandwich enzyme-linked immunosorbent assay(ELISA R and D system).The relationship was analyzed between PET/CT images for LC T-staging and metastasis(lymph nodes and distance)and serum VEGF expression. RESULTS Based on PET/CT images for LC T-staging,11 cases were staged as T1,9 as T2,18 as T3 and 15 as T4.Mediastinal nodal metastases were found in 22 patients,and distance metastasis in 9.The serum VEGF level in the LC patients was(378.02±180.79)ng/L,showing that there was a significant difference between the patients and healthy subjects(P<0.05). There was no significant difference in the level of serum VEGF between different low T-staged(T1,T2)patients.However,the level of serum VEGF was significantly different between the low T-staged(T1,T2)and high T-staged (T3,T4)patients(P<0.05).The level of the serum VEGF protein in the patients with mediastinal nodal metastasis was(561.50±104.55)ng/L,and indicating that there was a statistical significance(t=12.21,P<0.05)compared to those in the non-metastatic group.The level of serum VEGF in the patients with distance metastasis was(614.11±158.81)ng/L,demonstrating that there was a significant difference(t=5.30,P<0.05)compared to those in the nondistant metastatic group. CONCLUSION ① There is a high level of serum VEGF expression in LC patients.②There is a correlation between metastases(lymph nodes and distance)and the level of serum VEGF. ③ With an upgrade of the TNM-stage,the level of serum VEGF protein is elevated.

Effect of radical surgery combined with pre- or postoperative radiotherapy in treatment of resectable rectal cancer

Objective： This study was done to compare between the effect of preoperative radiotherapy and postoperative radiotherapy in treatment of resectable rectal carcinoma. The primary endpoints are local recurrence rate, overall survival （OS） and disease free survival （DFS）. The secondary endpoints are to evaluate down-staging, treatment toxicity, and ability to do sphincter preservation, aiming at choosing the optimal treatment modality. Methods： This study included 100 patients with resectable rectal carcinoma who presented to Surgical Gastro Entrology Center and Clinical Oncology and Nuclear Medicine Department, Mansoura University during the period between January 2007 and September 2009. The included patients were randomized in two groups; group h 50 patients received preoperative radiotherapy and group Ih 50 patients received post- operative radiotherapy. Concurrent 5-fluorouracil-based chemotherapy was given to all patients. Two major types of surgery were done： abdomino-perineal resection with a permanent colostomy and low anterior resection with colorectal or coloanal anastomosis. Results： Preoperative radiotherapy resulted in pathologic complete response in 3 patients. T down-staging occurred in 18 out of 50 patients （36%） with statistically significant difference （P = 0.008）. N down-staging occurred in 10 out of 24 patients. Sphincter preservation was more in group I. Delayed wound healing was the most common postoperative complication in group I with no significant difference. After a median follow up of 18 months, local recurrence rate and distant metastasis were higher in group I1. The 2-year disease free survival was 72% and 60% in group I and II respectively with no statistically significant difference between both groups. Conclusion： This study concluded that preoperative radiotherapy is better than postoperative radiotherapy as regard local control, sphincter preservation with higher disease free survival and overall survival. No difference in treatment toxicity between both groups.

Clinical study on gefitinib combined with γ-ray stereotactic radiotherapy for senile patients with adenocarcinoma of lung as the first-line regimen

Objective: The aim of our study was to evaluate the efficacy and safety of gefitinib combined with γ-ray stereo-tactic radiotherapy for senile patients with adenocarcinoma of lung as the first-line regimen. Methods: The 153 senile patients with adenocarcinoma of lung were divided into 4 groups according to the therapy method. Group A was the 35 patients treated with gefitinib combined with γ-ray stereotactic radiotherapy. Group B was the 45 patients treated with γ-ray stereotactic radio-therapy. Group C was the 42 patients treated with gefitinib. Group D was the 31 patients treated with best supportive therapy. The patients received gefitinib of 250 mg/d from the first day until disease progression or other reasons. The patients were treated with γ-ray stereotactic radiotherapy from the second day. Dose curve of this group of cases was 50%-80%. Encircled dose was 4.0-6.5 Gy per fraction and the range of total dose was 36-48 Gy. The total number of treatment was 8-12 and treated six times every week. Results: All the patients were examined by enhanced double helix CT at the second month. The tumor response rate (RR) of group A was 68.6% (24/35). Disease control rate (DCR) was 88.6% (31/35). The median survival time (MST) was 13.4 months (range 3-34 months ) and the progression-free survival (PFS) was 7.8 months. The overall 1-year survival rate was 40.0% (14/35). The main side effects included skin rash and diarrhea. The RR of group B was 51.1% (23/45). DCR was 71.1% (32/45). MST was 9.6 months (range, 3-18 months ) and PFS was 5.3 months. The overall 1-year survival rate was 15.6 % (7/45). The RR of group C was 40.5 % (17/42). DCR was 61.9% (26 /42). MST was 10.3 months (range, 3-26 months ) and PFS was 5.1 months. The overall 1-year survival rate was 35.7 % (15/42). The main side effects included skin rash and diarrhea. The MST of group D was 5.6 months (range, 2-11 months ) and PFS was 1.7 months. The overall 1-year survival rate was 0. The short-term therapeutic effects (RR) of group A was higher than group C (P = 0.014 < 0.05, χ2 = 6.053) but has no significant difference with group B (P = 0.116 > 0.05, χ2 = 2.477). The long-term therapeutic effects (overall 1-year survival rate) of group A was higher than group B (P = 0.014 < 0.05, χ2 = 6.077) but has no significant difference with group C (P = 0.642 > 0.05, χ2 = 0.216). Conclusion: Gefitinib combined with γ-ray stereotactic radiotherapy is feasible and effective for treatment in senile patients with adenocarcinoma of lung as the first-line regimen.

Treatment regimen design in clinical radiotherapy for hepatoma

Recently, the paper by Wang et at published in World Journal of Gastroenterology has given rise to great interest of many researchers. It is well known that hepatoma is one of the lethal diseases with a high incidence in the world, especially in Asia. Radiotherapy is the main treatment modality of hepatoma in clinical practice. Unfortunately, intrinsic radiosensitivity of cancer cells is not fully understood, though a large number of papers on it are now available. Yang and colleagues 21 have developed the premature chromosome condensation technique for clinical radiotherapy of hepatoma. A precise and quick measurement of cell radiosensitivity can detect the highrisk results after exposure to a large dose.

Efficacy and nursing of stereotactic radiotherapy in lung cancer patients with brain metastases

Objective: To observe the efficacy of stereotactic radiotherapy (SRT) in lung cancer patients with brain metas-tases and explore the nursing for those patients. Methods: From June 2002 to December 2006, 43 patients of lung cancer with brain metastases were treated with SRT, 8 of them were treated with the association of whole-brain radiotherapy (WBRT) and 6 of them were treated with combination of chemotherapy. During the period of SRT, the patients were applied with active psychological nursing and diet nursing. We also tried to prevent patients from epicranium injury, and meanwhile, patients were asked to took active convalesce exercise. Results: All patients finished SRT without serious reaction and complication. Local control rate was 81.4%, nervous system symptoms relief rate was 76.7% and KPS score was raised significantly. Survival time ranged from 2 to 34 months, median survival time was 8.5 months, and 6-month, 1-and 2-year survival rates were 58.9%, 26.2%, and 6.0% respectively. Conclusion: SRT was one of the effective palliation treatments for the lung cancer patients with brain metastases, and with the assistance of effective nursing, which would prolong their survival time and improved quality of life.

Clinical study on concurrent and sequential therapy of intensity modulated radiation therapy (IMRT) combined with NP regimen chemotherapy in the treatment of middle and advanced non-small cell lung cancer

Objective: To evaluate the clinical effects of concurrent and sequential therapy for middle and advanced stage non-small cell lung cancer (NSCLC) useing IMRT combined with NP regimen chemotherapy. Methods: Eighty patients with middle and advanced stage NSCLC were randomized into two groups. Forty patients were underwent sequential therapy and other 40 patients were underwent concurrent therapy. IMRT was used in radiotherapy and NP regimen of vinorelbine+cispatin (NP) was used in chemotherapy. Results: (1) The overall response (CR+PR) rate was 75% in concurrent group and 45% in sequential group (P<0.05); (2) The treatment courses were 84 days and 140 days for concurrent group and sequential group respectively (P<0.05); (3) One-year survival rate in concurrent group was 72.4% and 52.3% in sequential group respectively; (4) The toxic effects can be tolerable by all of patients. Conclusion: The concurrent chemo-radiotherapy has better overall re- sponse, one-year survival rate and shorter treatment course than the sequential chemo-radiotherapy, so it is a better method for the treatment of middle and advanced stage NSCLC, but the long term survival rate will be studied.

Clinical analysis of 45 cases of surgical treatment for inner thigh primary soft tissue sarcoma

Objective: We aimed to study the relationship between clinical effect and surgical methods of inner thigh primary soft tissue sarcomas. Methods: Wide or radical resection were performed in 45 cases of soft tissue sarcomas, including 20 cases of postoperative recurrence after radiation therapy, 7 cases of first treatment. Thirty-six cases received 4–6 cycles of postoperative chemotherapy. Results: Thirty-eight of 45 cases were followed up for 1–5 years, with 5 case of recurrence and 6 cases of distant metastasis. Conclusion: The inner thigh primary soft tissue sarcoma can be effectively treated with wide or radical resection.